Janssen Biotech, Inc. | Patient Daily

Janssen Biotech, Inc.

Nicholas Gueguen | Aug 17, 2017

FDA gives Imbruvica go-ahead to aid patients with chronic graft versus host disease

Jamie Barrand | Mar 9, 2016

FDA approves Imbruvica as first-line therapy for chronic lymphocytic leukemia

Jamie Barrand | Sep 17, 2015

Janssen's multiple myeloma drug accepted for FDA priority review

Trending

Patient Daily | Oct 14, 2025

Mackinac Center raises concerns over federal 340B drug pricing program’s market impact

+ Pharmaceuticals

Patient Daily | Oct 13, 2025

Cardinal Institute policy analyst: 340B program 'has quietly become a $40B side business'

Patient Daily | Oct 14, 2025

Delaware federal court dismisses Eli Lilly lawsuit against Strive Pharmacy

Patient Daily | Oct 9, 2025

AI takes center stage at ASCENT ENT conference, reshaping marketing and operations